1. Economopoulou, P., de Bree, R., Kotsantis, I., and Psyrri, A. (2019). Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting. Front Oncol 9, 827. doi: 10.3389/fonc.2019.00827.
2. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6), 394-424. doi: 10.3322/caac.21492.
3. Solomon, B., Young, R.J., and Rischin, D. (2018). Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol 52(Pt 2), 228-240. doi: 10.1016/j.semcancer.2018.01.008.
4. Gavrielatou, N., Doumas, S., Economopoulou, P., Foukas, P.G., and Psyrri, A. (2020). Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev 84, 101977. doi: 10.1016/j.ctrv.2020.101977.
5. Ferris, R.L., Blumenschein, G., Jr., Fayette, J., Guigay, J., Colevas, A.D., Licitra, L., et al. (2018). Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81, 45-51. doi: 10.1016/j.oraloncology.2018.04.008.
6. Burtness, B., Harrington, K.J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Jr., et al. (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212), 1915-1928. doi: 10.1016/s0140-6736(19)32591-7.
7. Liu, B., Ye, B., Yang, L., Zhu, X., Huang, G., Zhu, P., et al. (2017). Long noncoding RNA lncKdm2b is required for ILC3 maintenance by initiation of Zfp292 expression. Nat Immunol 18(5), 499-508. doi: 10.1038/ni.3712.
8. Wang, K.C., and Chang, H.Y. (2011). Molecular mechanisms of long noncoding RNAs. Mol Cell 43(6), 904-914. doi: 10.1016/j.molcel.2011.08.018.
9. Prensner, J.R., and Chinnaiyan, A.M. (2011). The emergence of lncRNAs in cancer biology. Cancer Discov 1(5), 391-407. doi: 10.1158/2159-8290.Cd-11-0209.
10. Zhao, W., Luo, J., and Jiao, S. (2014). Comprehensive characterization of cancer subtype associated long non-coding RNAs and their clinical implications. Sci Rep 4, 6591. doi: 10.1038/srep06591.
11. Xing, C., Sun, S.G., Yue, Z.Q., and Bai, F. (2021). Role of lncRNA LUCAT1 in cancer. Biomed Pharmacother 134, 111158. doi: 10.1016/j.biopha.2020.111158.
12. Denaro, N., Merlano, M.C., and Lo Nigro, C. (2019). Long noncoding RNAs as regulators of cancer immunity. Mol Oncol 13(1), 61-73. doi: 10.1002/1878-0261.12413.
13. Chen, Y.G., Satpathy, A.T., and Chang, H.Y. (2017). Gene regulation in the immune system by long noncoding RNAs. Nat Immunol 18(9), 962-972. doi: 10.1038/ni.3771.
14. Li, Y., Jiang, T., Zhou, W., Li, J., Li, X., Wang, Q., et al. (2020). Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers. Nat Commun 11(1), 1000. doi: 10.1038/s41467-020-14802-2.
15. Xu, W.H., Xu, Y., Wang, J., Wan, F.N., Wang, H.K., Cao, D.L., et al. (2019). Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. Aging (Albany NY) 11(17), 6999-7020. doi: 10.18632/aging.102233.
16. Zhou, R., Zhang, J., Zeng, D., Sun, H., Rong, X., Shi, M., et al. (2019). Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I-III colon cancer. Cancer Immunol Immunother 68(3), 433-442. doi: 10.1007/s00262-018-2289-7.
17. Ma, W., Zhao, F., Yu, X., Guan, S., Suo, H., Tao, Z., et al. (2020). Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature. J Transl Med 18(1), 442. doi: 10.1186/s12967-020-02522-6.
18. Wang, W., Zhao, Z., Yang, F., Wang, H., Wu, F., Liang, T., et al. (2018). An immune-related lncRNA signature for patients with anaplastic gliomas. J Neurooncol 136(2), 263-271. doi: 10.1007/s11060-017-2667-6.
19. Khadirnaikar, S., Kumar, P., Pandi, S.N., Malik, R., Dhanasekaran, S.M., and Shukla, S.K. (2019). Immune associated LncRNAs identify novel prognostic subtypes of renal clear cell carcinoma. Mol Carcinog 58(4), 544-553. doi: 10.1002/mc.22949.
20. Shen, Y., Peng, X., and Shen, C. (2020). Identification and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics 112(3), 2640-2646. doi: 10.1016/j.ygeno.2020.02.015.
21. Jiang, H., Ma, B., Xu, W., Luo, Y., Wang, X., Wen, S., et al. (2020). A Novel Three-lncRNA Signature Predicts the Overall Survival of HNSCC Patients. Ann Surg Oncol. doi: 10.1245/s10434-020-09210-1.
22. Yang, B., Shen, J., Xu, L., Chen, Y., Che, X., Qu, X., et al. (2019). Genome-Wide Identification of a Novel Eight-lncRNA Signature to Improve Prognostic Prediction in Head and Neck Squamous Cell Carcinoma. Front Oncol 9, 898. doi: 10.3389/fonc.2019.00898.
23. Vigneswaran, N., and Williams, M.D. (2014). Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am 26(2), 123-141. doi: 10.1016/j.coms.2014.01.001.
24. Lee, K., Chang, J.W., Oh, C., Liu, L., Jung, S.N., Won, H.R., et al. (2020). HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis. Eur J Surg Oncol 46(6), 1066-1073. doi: 10.1016/j.ejso.2019.12.009.
25. Wang, J., Chen, X., Tian, Y., Zhu, G., Qin, Y., Chen, X., et al. (2020). Six-gene signature for predicting survival in patients with head and neck squamous cell carcinoma. Aging (Albany NY) 12(1), 767-783. doi: 10.18632/aging.102655.
26. Ghafouri-Fard, S., and Taheri, M. (2020). Long non-coding RNA signature in gastric cancer. Exp Mol Pathol 113, 104365. doi: 10.1016/j.yexmp.2019.104365.
27. Luan, F., Chen, W., Chen, M., Yan, J., Chen, H., Yu, H., et al. (2019). An autophagy-related long non-coding RNA signature for glioma. FEBS Open Bio 9(4), 653-667. doi: 10.1002/2211-5463.12601.
28. Tutino, V.M., Poppenberg, K.E., Damiano, R.J., Patel, T.R., Waqas, M., Dmytriw, A.A., et al. (2020). Characterization of Long Non-coding RNA Signatures of Intracranial Aneurysm in Circulating Whole Blood. Mol Diagn Ther 24(6), 723-736. doi: 10.1007/s40291-020-00494-3.
29. Hong, W., Liang, L., Gu, Y., Qi, Z., Qiu, H., Yang, X., et al. (2020). Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma. Mol Ther Nucleic Acids 22, 937-947. doi: 10.1016/j.omtn.2020.10.002.
30. Kaufmann, S.H.E. (2019). Immunology's Coming of Age. Front Immunol 10, 684. doi: 10.3389/fimmu.2019.00684.
31. Hur, K., Kim, S.H., and Kim, J.M. (2019). Potential Implications of Long Noncoding RNAs in Autoimmune Diseases. Immune Netw 19(1), e4. doi: 10.4110/in.2019.19.e4.
32. Hu, Q., Ye, Y., Chan, L.C., Li, Y., Liang, K., Lin, A., et al. (2019). Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol 20(7), 835-851. doi: 10.1038/s41590-019-0400-7.
33. Huang, D., Chen, J., Yang, L., Ouyang, Q., Li, J., Lao, L., et al. (2018). NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol 19(10), 1112-1125. doi: 10.1038/s41590-018-0207-y.
34. Xia, P., Li, Q., Wu, G., and Huang, Y. (2021). An Immune-Related lncRNA Signature to Predict Survival In Glioma Patients. Cell Mol Neurobiol 41(2), 365-375. doi: 10.1007/s10571-020-00857-8.
35. Chen, Q., Hu, L., Huang, D., Chen, K., Qiu, X., and Qiu, B. (2020). Six-lncRNA Immune Prognostic Signature for Cervical Cancer. Front Genet 11, 533628. doi: 10.3389/fgene.2020.533628.
36. Tan, J., Liu, L., Zuo, Z., Song, B., Cai, T., Ding, D., et al. (2020). Overexpression of novel long intergenic non-coding RNA LINC02454 is associated with a poor prognosis in papillary thyroid cancer. Oncol Rep 44(4), 1489-1501. doi: 10.3892/or.2020.7712.
37. Zhou, J.F., Shi, Y.T., Wang, H.G., Yang, X.Z., and Wu, S.N. (2019). Overexpression of long noncoding RNA HOXC13-AS and its prognostic significance in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 23(17), 7369-7374. doi: 10.26355/eurrev_201909_18843.
38. Li, X., Wang, Q., Rui, Y., Zhang, C., Wang, W., Gu, J., et al. (2019). HOXC13-AS promotes breast cancer cell growth through regulating miR-497-5p/PTEN axis. J Cell Physiol 234(12), 22343-22351. doi: 10.1002/jcp.28800.
39. Jiang, D., Zhang, Y., Yang, L., Lu, W., Mai, L., Guo, H., et al. (2020). Long noncoding RNA HCG22 suppresses proliferation and metastasis of bladder cancer cells by regulation of PTBP1. J Cell Physiol 235(2), 1711-1722. doi: 10.1002/jcp.29090.
40. Li, X., Xiao, X., Chang, R., and Zhang, C. (2020). Comprehensive bioinformatics analysis identifies lncRNA HCG22 as a migration inhibitor in esophageal squamous cell carcinoma. J Cell Biochem 121(1), 468-481. doi: 10.1002/jcb.29218.
41. Song, D., Wu, S., Hu, H., Dai, X., and Wang, X. (2021). Long Noncoding RNA MIAT Regulates the Process of Laryngeal Squamous Cell Carcinoma Through Regulation of miR-147a/BCOR. Arch Med Res. doi: 10.1016/j.arcmed.2020.12.001.
42. Song, F., Yang, Y., and Liu, J. (2021). Long non-coding RNA MIAT promotes the proliferation and invasion of laryngeal squamous cell carcinoma cells by sponging microRNA-613. Exp Ther Med 21(3), 232. doi: 10.3892/etm.2021.9663.
43. Liu, X., Wu, S., Yang, Y., Zhao, M., Zhu, G., and Hou, Z. (2017). The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacother 95, 55-61. doi: 10.1016/j.biopha.2017.08.003.
44. Vassilakopoulou, M., Avgeris, M., Velcheti, V., Kotoula, V., Rampias, T., Chatzopoulos, K., et al. (2016). Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. Clin Cancer Res 22(3), 704-713. doi: 10.1158/1078-0432.Ccr-15-1543.
45. Qi, Y., Deng, G., Xu, P., Zhang, H., Yuan, F., Geng, R., et al. (2019). HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma. Oncol Rep 42(6), 2309-2322. doi: 10.3892/or.2019.7343.
46. Dong, X., Gu, D.N., Wang, O., and Ye, Z. (2020). LAGE3 correlates with tumorigenic immune infiltrates in the clear cell renal cell carcinoma microenvironment. Int Immunopharmacol 87, 106793. doi: 10.1016/j.intimp.2020.106793.
47. Li, T., Fan, J., Wang, B., Traugh, N., Chen, Q., Liu, J.S., et al. (2017). TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res 77(21), e108-e110. doi: 10.1158/0008-5472.Can-17-0307.
48. Becht, E., Giraldo, N.A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., et al. (2016). Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17(1), 218. doi: 10.1186/s13059-016-1070-5.
49. Racle, J., de Jonge, K., Baumgaertner, P., Speiser, D.E., and Gfeller, D. (2017). Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife 6. doi: 10.7554/eLife.26476.
50. Zhang, C., Li, Z., Qi, F., Hu, X., and Luo, J. (2019). Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma. Ann Transl Med 7(22), 648. doi: 10.21037/atm.2019.10.84.
51. Tamminga, M., Hiltermann, T.J.N., Schuuring, E., Timens, W., Fehrmann, R.S., and Groen, H.J. (2020). Immune microenvironment composition in non-small cell lung cancer and its association with survival. Clin Transl Immunology 9(6), e1142. doi: 10.1002/cti2.1142.
52. Wang, S., Zhang, Q., Yu, C., Cao, Y., Zuo, Y., and Yang, L. (2021). Immune cell infiltration-based signature for prognosis and immunogenomic analysis in breast cancer. Brief Bioinform 22(2), 2020-2031. doi: 10.1093/bib/bbaa026.